• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

包括手术切除在内的多模态治疗非常局部晚期鼻窦癌。

Including Surgical Resection in the Multimodal Management of Very Locally Advanced Sinonasal Cancer.

机构信息

Department of Radiation Oncology, NYU Langone Health, New York, New York, USA.

Department of Otolaryngology, NYU Langone Health, New York, New York, USA.

出版信息

Otolaryngol Head Neck Surg. 2022 Sep;167(3):494-500. doi: 10.1177/01945998211067503. Epub 2021 Dec 28.

DOI:10.1177/01945998211067503
PMID:34962843
Abstract

OBJECTIVE

Sinonasal cancer often presents as locoregionally advanced disease. National guidelines recommend management of stage T4b tumors with systemic therapy and radiotherapy, but recent studies suggest that including surgical resection in the multimodal treatment of these tumors may improve local control and survival. We queried the National Cancer Database to examine patterns of care and outcomes in T4b sinonasal squamous cell carcinoma (SCC).

STUDY DESIGN

Prospectively gathered data.

SETTING

National Cancer Database.

METHODS

Patients with T4b N0-3 M0 sinonasal squamous cell carcinoma diagnosed in 2004 to 2016 were stratified between those who received chemoradiotherapy and those who underwent surgical resection with neoadjuvant or adjuvant treatment. The overall survival of each cohort was assessed via Kaplan-Meier analysis and Cox proportional hazard models, with repeat analysis after reweighting of data via inverse probability of treatment weighting.

RESULTS

Among 805 patients included in analysis, 2-year overall survival for patients undergoing surgical resection was 60.8% (95% CI, 56.1%-65.9%), while for patients undergoing chemoradiotherapy it was 46.7% (95% CI, 41.9%-52.0%). On Cox regression analysis, the inclusion of surgery in management was associated with improved survival in univariate analysis (hazard ratio [HR], 0.723 [95% CI, 0.606-0.862]; < .001) and multivariate analysis (HR, 0.739 [95% CI, 0.618-0.885]; = .001). Results with reweighted data were consistent in univariate analysis (HR, 0.765 [95% CI, 0.636-0.920]; = .004]).

CONCLUSION

Surgical treatment with neoadjuvant or adjuvant treatment for stage T4b sinonasal SCC was associated with promising survival outcomes, suggesting a role for incorporating surgery in treatment of select T4b SCC, particularly when removal of all macroscopic disease is feasible.

摘要

目的

鼻窦癌常表现为局部晚期疾病。国家指南建议对 T4b 期肿瘤采用全身治疗和放疗进行治疗,但最近的研究表明,在这些肿瘤的多模式治疗中加入手术切除可能会改善局部控制和生存率。我们查询了国家癌症数据库,以检查 T4b 鼻窦鳞状细胞癌(SCC)的治疗模式和结果。

研究设计

前瞻性收集数据。

设置

国家癌症数据库。

方法

2004 年至 2016 年间诊断为 T4bN0-3M0 鼻窦鳞状细胞癌的患者分为接受放化疗和接受新辅助或辅助治疗的手术切除组。通过 Kaplan-Meier 分析和 Cox 比例风险模型评估每个队列的总生存率,并通过治疗加权逆概率重复分析数据后进行重复分析。

结果

在纳入分析的 805 名患者中,接受手术切除的患者 2 年总生存率为 60.8%(95%CI,56.1%-65.9%),而接受放化疗的患者为 46.7%(95%CI,41.9%-52.0%)。在 Cox 回归分析中,在单因素分析中,将手术纳入治疗与生存改善相关(风险比[HR],0.723[95%CI,0.606-0.862];<0.001)和多因素分析(HR,0.739[95%CI,0.618-0.885];=0.001)。重新加权数据的单因素分析结果一致(HR,0.765[95%CI,0.636-0.920];=0.004)。

结论

对于 T4b 鼻窦 SCC,采用新辅助或辅助治疗的手术治疗与有希望的生存结果相关,这表明在选择 T4b SCC 时,将手术纳入治疗具有一定作用,特别是当可以切除所有肉眼可见的疾病时。

相似文献

1
Including Surgical Resection in the Multimodal Management of Very Locally Advanced Sinonasal Cancer.包括手术切除在内的多模态治疗非常局部晚期鼻窦癌。
Otolaryngol Head Neck Surg. 2022 Sep;167(3):494-500. doi: 10.1177/01945998211067503. Epub 2021 Dec 28.
2
Sinonasal Squamous Cell Carcinoma Outcomes: Does Treatment at a High-Volume Center Confer Survival Benefit?鼻窦鳞状细胞癌的预后:在高容量中心治疗是否有生存获益?
Otolaryngol Head Neck Surg. 2020 Nov;163(5):986-991. doi: 10.1177/0194599820935395. Epub 2020 Jun 30.
3
T4b Sinonasal Squamous Cell Carcinoma: Surgery Plus Radiotherapy May Contribute to Prolonged Survival.T4b 鼻窦鳞状细胞癌:手术加放疗可能有助于延长生存时间。
Laryngoscope. 2023 Sep;133(9):2222-2231. doi: 10.1002/lary.30545. Epub 2022 Dec 30.
4
A comprehensive comparative analysis of treatment modalities for sinonasal malignancies.鼻窦恶性肿瘤治疗方式的全面比较分析
Cancer. 2017 Aug 15;123(16):3040-3049. doi: 10.1002/cncr.30686. Epub 2017 Apr 3.
5
Neoadjuvant chemotherapy for locoregionally advanced squamous cell carcinoma of the paranasal sinuses.新辅助化疗用于治疗局部晚期鼻窦鳞状细胞癌。
Cancer. 2021 Jun 1;127(11):1788-1795. doi: 10.1002/cncr.33452. Epub 2021 Feb 10.
6
Survival Impact of Surgical Resection in Locally Advanced T4b Oral Squamous Cell Carcinoma.局部晚期 T4b 口腔鳞状细胞癌手术切除的生存影响。
Laryngoscope. 2021 Jul;131(7):E2266-E2274. doi: 10.1002/lary.29394. Epub 2021 Jan 18.
7
Outcomes of Primary Versus Salvage Surgery for Sinonasal Malignancies: A Population-Based Analysis.原发性与挽救性手术治疗鼻窦恶性肿瘤的结局:基于人群的分析。
Laryngoscope. 2021 Mar;131(3):E710-E718. doi: 10.1002/lary.28925. Epub 2020 Jul 24.
8
Neoadjuvant Superselective Intra-Arterial Cisplatin Chemoradiotherapy Combined With Surgery in Patients With T4 Squamous Cell Carcinoma of the Maxillary Sinus.新辅助超选择性动脉内顺铂化疗联合放疗并手术治疗上颌窦 T4 期鳞状细胞癌。
J Oral Maxillofac Surg. 2022 Aug;80(8):1445-1450. doi: 10.1016/j.joms.2022.04.014. Epub 2022 May 2.
9
Radical Exenteration of the Skull Base for End-Stage, Locally Advanced Sinonasal Malignancies: Challenging the Dictum of Unresectability.颅底根治性切除术治疗终末期、局部晚期鼻腔鼻窦恶性肿瘤:对不可切除性原则的挑战。
World Neurosurg. 2021 Jun;150:e102-e107. doi: 10.1016/j.wneu.2021.02.092. Epub 2021 Feb 26.
10
A Multicentre UK Study of Outcomes for Locally Advanced Sinonasal Squamous Cell Carcinoma Treated with Adjuvant or Definitive Intensity-modulated Radiotherapy.一项英国多中心研究:局部晚期鼻-鼻窦鳞状细胞癌采用辅助或根治性调强放疗的疗效。
Clin Oncol (R Coll Radiol). 2021 Oct;33(10):e450-e461. doi: 10.1016/j.clon.2021.05.012. Epub 2021 Jun 17.

引用本文的文献

1
Surgical resection and overall survival in cT4b sinonasal non-squamous cell carcinoma.cT4b期鼻窦非鳞状细胞癌的手术切除与总生存期
Laryngoscope Investig Otolaryngol. 2024 Oct 23;9(5):e70025. doi: 10.1002/lio2.70025. eCollection 2024 Oct.
2
Real-Life Prognosis of Sinonasal Tumors.鼻窦肿瘤的实际预后
J Pers Med. 2024 Apr 24;14(5):444. doi: 10.3390/jpm14050444.